Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan
All eyes are on Shire in its first quarter of reporting separate figures for its neuroscience division as Takeda ramps up the takeover pressure, while BMS, AbbVie, Sanofi, and Allergan primes pipeline for revenue growth.
You may also be interested in...
Financials are holding up well despite generics launching against multiple Allergan products, but with stock price falling the company is conducting a strategic review to make sure it isn't missing out on any alternative business strategies that could boost the enterprise's value.
During a mixed review by the US FDA's Arthritis Advisory Committee, panelists suggested that risks potentially associated with Lilly/Incyte's JAK inhibitor would be acceptable for a more limited patient population.
Data from AACR puts use of tumor mutation burden as biomarker for lung cancer outcomes in spotlight, but some experts argue the test is not ready for prime time.